Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander T Cohen

Showing results (61-70 of 227) with videos related to

Pageof 23
Sort By:
Advances in Therapy|July 9, 2021
Correction to: Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFYAlexander T Cohen, Sharon Pan, Wonkyung Byon, et al.
Journal of Market Access & Health Policy|July 24, 2018
Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UKEmilie Clay, Aurélien Jamotte, Peter Verhamme, et al.
Advances in Therapy|April 23, 2021
Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFYAlexander T Cohen, Sharon Pan, Wonkyung Byon, et al.
BMC Health Services Research|January 25, 2017
Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrencesTereza Lanitis, Robert Leipold, Melissa Hamilton, et al.
Thrombosis and Haemostasis|October 9, 2015
Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trialXianchen Liu, John Thompson, Hemant Phatak, et al.
Clinical Therapeutics|February 29, 2016
Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of RecurrenceTereza Lanitis, Robert Leipold, Melissa Hamilton, et al.
Pharmacoeconomics|December 23, 2018
Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United StatesHolly Guy, Vicki Laskier, Mark Fisher, et al.
ESMO Open|November 24, 2020
Prevention of venous thromboembolism in ambulatory patients with cancerAlok A Khorana, Alexander T Cohen, Marc Carrier, et al.
Journal of Medical Economics|July 18, 2019
Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysisVicki Laskier, Holly Guy, Mark Fisher, et al.
BMJ (Clinical Research Ed.)|December 2, 2016
Testosterone treatment and risk of venous thromboembolism: population based case-control studyCarlos Martinez, Samy Suissa, Stephan Rietbrock, et al.
Pageof 23

Showing results (61-70 of 227) with videos related to

Sort By:
Pageof 23
Advances in Therapy|July 9, 2021
Correction to: Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFYAlexander T Cohen, Sharon Pan, Wonkyung Byon, et al.
Journal of Market Access & Health Policy|July 24, 2018
Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UKEmilie Clay, Aurélien Jamotte, Peter Verhamme, et al.
Advances in Therapy|April 23, 2021
Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFYAlexander T Cohen, Sharon Pan, Wonkyung Byon, et al.
BMC Health Services Research|January 25, 2017
Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrencesTereza Lanitis, Robert Leipold, Melissa Hamilton, et al.
Thrombosis and Haemostasis|October 9, 2015
Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trialXianchen Liu, John Thompson, Hemant Phatak, et al.
Clinical Therapeutics|February 29, 2016
Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of RecurrenceTereza Lanitis, Robert Leipold, Melissa Hamilton, et al.
Pharmacoeconomics|December 23, 2018
Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United StatesHolly Guy, Vicki Laskier, Mark Fisher, et al.
ESMO Open|November 24, 2020
Prevention of venous thromboembolism in ambulatory patients with cancerAlok A Khorana, Alexander T Cohen, Marc Carrier, et al.
Journal of Medical Economics|July 18, 2019
Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysisVicki Laskier, Holly Guy, Mark Fisher, et al.
BMJ (Clinical Research Ed.)|December 2, 2016
Testosterone treatment and risk of venous thromboembolism: population based case-control studyCarlos Martinez, Samy Suissa, Stephan Rietbrock, et al.
Pageof 23